Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: CeraMed OsteoGraf CS-300

This article was originally published in The Gray Sheet

Executive Summary

CeraMed OsteoGraf CS-300: P-15 peptide is described in initial draft labeling as a "peptide which mimics the cell binding region of collagen." The Jan. 19 issue of "The Gray Sheet" incorrectly reported that draft labeling does not reference cell binding. In addition, the OsteoGraf N-300 and CS-300 contain inorganic rather than organic bovine derived hydroxyapatite particles as previously reported...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel